Skip to main content
. 2016 Jul 22;6:30220. doi: 10.1038/srep30220

Table 3. Summary of overall results and subgroup for the association between the NF-κB1-94 ins/del ATTG promoter polymorphism and cancer risk.

  No. Sample size (N)
 DD+DI vs. II
 DD vs. DI+II
 DD vs. II
 DI vs. II
 D vs. I
Case Control OR (95% CI) POR a OR (95% CI) POR a OR (95% CI) POR a OR (95% CI) POR a OR (95% CI) POR a
Overall 42 18,222 24,778 0.86 (0.79–0.95) 0.002 0.84 (0.74–0.94) 0.003 0.77 (0.66–0.90) 0.001 0.90 (0.83–0.98) 0.011 0.89 (0.83–0.96) 0.002
Control source
 PB 10 5,369 8,212 0.90 (0.72–1.13) 0.354 0.77 (0.62–0.96) 0.02 0.72 (0.52–1.01) 0.053 0.96 (0.78–1.17) 0.689 0.89 (0.76–1.04) 0.15
 HB 29 12,463 15,976 0.85 (0.77–0.95) 0.003 0.86 (0.74–0.99) 0.04 0.78 (0.65–0.93) 0.007 0.88 (0.81–0.96) 0.004 0.89 (0.81–0.97) 0.006
Ethnicity
 Caucasian 12 3,413 6,887 1.20 (1.1–1.31) <0.0001 1.03 (0.92–1.16) 0.583 1.15 (1.01–1.31) 0.03 1.22 (1.11–1.34) <0.0001 1.11 (1.04–1.17) 0.001
 Asian 30 14,809 17,891 0.77 (0.70–0.86) <0.0001 0.77 (0.67–0.90) 0.001 0.66 (0.55–0.80) <0.0001 0.85 (0.81–0.90) <0.0001 0.82 (0.76–0.90) <0.0001
Genotyping methods
 PCR-RFLP 11 5,450 6,525 0.75 (0.62–0.90) 0.002 0.72 (0.60–0.87) 0.001 0.62 (0.47–0.82) 0.001 0.81 (0.70–0.94) 0.005 0.87 (0.80–0.95) 0.001
 MassARRAY 3 998 1,096 0.77 (0.44–1.32) 0.334 0.93 (0.43–2.01) 0.862 0.77 (0.29–2.07) 0.608 0.75 (0.53–1.07) 0.111 0.87 (0.80–0.95) 0.609
 TaqMan 14 8,505 12,059 0.95 (0.83–1.09) 0.446 0.99 (0.83–1.21) 0.977 0.95 (0.76–1.19) 0.654 0.95 (0.84–1.07) 0.375 0.87 (0.80–0.95) 0.685
 PCR-PAGE 6 1,284 1,599   0.08 0.65 (0.50–0.85) 0.002 0.58 (0.39–0.86) 0.008 0.86 (0.66–1.12) 0.257 0.87 (0.80–0.95) 0.015
 PCR-CGE 2 241 349 0.70 (0.50–0.98) 0.037 0.61 (0.26–1.40) 0.239 0.51 (0.23–1.13) 0.096 0.78 (0.55–1.12) 0.174 0.87 (0.80–0.95) 0.017
 Pyrosequencing 4 593 1,228 1.18 (0.94–1.48) 0.146 0.96 (0.72–1.28) 0.756 1.06 (0.78–1.45) 0.693 1.23 (0.94–1.60) 0.125 0.87 (0.80–0.95) 0.364
Quality score
 <7 points 24 8,849 13,548   0.013 0.81 (0.71–0.91) 0.001 0.75 (0.63–0.89) 0.001 0.91 (0.82–1.01) 0.076 0.87 (0.80–0.95) 0.002
 >7 points 18 9,373 11,230 0.87 (0.74–1.01) 0.066 0.87 (0.70–1.08) 0.205 0.79 (0.60–1.04) 0.086 0.89 (0.78–1.01) 0.073 0.91 (0.80–1.03) 0.126
Cancer Type
 OSCC 2 674 721 0.60 (0.46–0.77) <0.0001 0.63 (0.49–0.81) <0.0001 0.49 (0.33–0.72) <0.0001 0.67 (0.51–0.88) 0.004 0.70 (0.60–0.82) <0.0001
 CRC 5 2,777 4,409 1.12 (0.85–1.48) 0.409 0.98 (0.76–1.26) 0.849 1.06 (0.74–1.52) 0.768 1.14 (0.87–1.49) 0.336 1.06 (0.88–1.27) 0.558
 BC 4 1,788 1,955   0.884 1.16 (0.68–1.97) 0.578 1.12 (0.64–1.96) 0.692 0.95 (0.81–1.11) 0.48 1.05 (0.82–1.36) 0.686
 GC 2 583 549 0.74 (0.24–2.31) 0.603 1.00 (0.26–3.85) 0.996 0.78 (0.12–5.12) 0.799 0.72 (0.33–1.57) 0.41 0.90 (0.34–2.24) 0.814
 HCC 3 961 2,530 0.59 (0.30–1.15) 0.119 0.67 (0.40–1.10) 0.114 0.50 (0.21–1.16) 0.106 0.65 (0.37–1.15) 0.137 0.69 (0.44–1.09) 0.114
 PC 4 2,207 2,358 0.79 (0.61–1.02) 0.074 0.89 (0.66–1.20) 0.447 0.72 (0.45–1.16) 0.177 0.84 (0.71–1.00) 0.05 0.88 (0.74–1.05) 0.149
 OC 4 1,463 1,573 0.67 (0.56–0.79) <0.0001 0.68 (0.52–0.89) 0.005 0.54 (0.40–0.73) <0.0001 0.73 (0.61–0.87) 0.001 0.75 (0.65–0.86) <0.0001
 LC 5 2,793 2,921 0.83 (0.67–1.03) 0.092 0.82 (0.54–1.26) 0.368 0.77 (0.48–1.26) 0.302 0.84 (0.74–0.96) 0.008 0.88 (0.70–1.09) 0.246
 NPC 3 1,573 2,182 0.82 (0.72–0.93) 0.003 0.74 (0.63–0.88) <0.0001 0.63 (0.49–0.81) <0.0001 0.63 (0.49–0.81) 0.067 0.83 (0.76–0.91) <0.0001
 RCC 2 1,356 1,895 1.01 (0.87–1.17) 0.892 1.01 (0.72–1.40) 0.973 1.06 (0.85–1.31) 0.625 1.07 (0.78–1.47) 0.688 1.02 (0.92–1.13) 0.71
 Other cancers 8 1,867 3,685 0.99 (0.78–1.27) 0.962 0.79 (0.59–1.05) 0.1 0.81 (0.55–1.21) 0.307 1.07 (0.86–1.31) 0.553 0.93 (0.77–1.13) 0.468

OR, odds ratio; CI, confidence interval.

P values in bold denotes significance.

aThe P values of Z test for odds ratios test.